RenovoRx Inc RNXT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RNXT is a good fit for your portfolio.
News
-
RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement
-
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
-
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026
-
RenovoRx Announces $11.1 Million at Market Private Placement
-
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024
-
RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024
-
RenovoRx Highlights Key Leadership Promotions
-
RenovoRx CEO Issues Letter to Shareholders
Trading Information
- Previous Close Price
- $1.21
- Day Range
- $1.21–1.38
- 52-Week Range
- $0.53–3.29
- Bid/Ask
- $1.20 / $1.31
- Market Cap
- $29.77 Mil
- Volume/Avg
- 27,483 / 40,514
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx’s patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 8
- Website
- https://www.renovorx.com
Valuation
|
Metric
|
RNXT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RNXT
|
|---|---|
Quick Ratio | 1.00 |
Current Ratio | 1.25 |
Interest Coverage | — |
Quick Ratio
RNXT
Profitability
|
Metric
|
RNXT
|
|---|---|
Return on Assets (Normalized) | −234.88% |
Return on Equity (Normalized) | −713.45% |
Return on Invested Capital (Normalized) | −720.54% |
Return on Assets
RNXT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dpczgtddd | Gzjn | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Yjppqqm | Pttdw | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hrkqxlrjv | Bsspdp | $97.8 Bil | |
MRNA
| Moderna Inc | Dpztlycwh | Xrb | $41.3 Bil | |
ARGX
| argenx SE ADR | Xylmpkxn | Kssxh | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Wttdrwqhs | Yrkk | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ygdxnyqnx | Kyjjdh | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qbhzclp | Qmppxs | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rlbcqxns | Ckpxlv | $12.5 Bil | |
INCY
| Incyte Corp | Wsvjvwspb | Dtjhbt | $11.6 Bil |